| Meena K Mohan, MD | |
|
3643 N Roxboro St, Durham, NC 27704-2702 | |
| (919) 470-4000 | |
| Not Available |
| Full Name | Meena K Mohan |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 3643 N Roxboro St, Durham, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134106834 | NPI | - | NPPES |
| 1250A | Other | BCBS | |
| 891250A | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 9901266 (North Carolina) | Secondary |
| 207R00000X | Internal Medicine | 9901266 (North Carolina) | Primary |
| Entity Name | Duke University Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376574798 PECOS PAC ID: 2567372345 Enrollment ID: O20031126000274 |
News Archive
Health care providers are constantly evolving treatments for complicated conditions to provide patients with the greatest amount of benefit while avoiding any adverse effects, like scarring.
Cherwell Laboratories, specialists in products for process validation and environmental monitoring will present their comprehensive product range at the Aseptic Preparation and Dispensing of Medicines (APDM) Course, Leeds Trinity University on 9th & 10th July 2013.
The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis.
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 5 days ago
| Entity Name | Hospital Physician Services - Southeast Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410385 PECOS PAC ID: 5597774554 Enrollment ID: O20100512000495 |
News Archive
Health care providers are constantly evolving treatments for complicated conditions to provide patients with the greatest amount of benefit while avoiding any adverse effects, like scarring.
Cherwell Laboratories, specialists in products for process validation and environmental monitoring will present their comprehensive product range at the Aseptic Preparation and Dispensing of Medicines (APDM) Course, Leeds Trinity University on 9th & 10th July 2013.
The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis.
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 5 days ago
| Entity Name | Med-x Consulting Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174017511 PECOS PAC ID: 9638419062 Enrollment ID: O20190322000300 |
News Archive
Health care providers are constantly evolving treatments for complicated conditions to provide patients with the greatest amount of benefit while avoiding any adverse effects, like scarring.
Cherwell Laboratories, specialists in products for process validation and environmental monitoring will present their comprehensive product range at the Aseptic Preparation and Dispensing of Medicines (APDM) Course, Leeds Trinity University on 9th & 10th July 2013.
The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis.
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meena K Mohan, MD 3643 N Roxboro St, Durham, NC 27704-2702 Ph: (919) 784-7093 | Meena K Mohan, MD 3643 N Roxboro St, Durham, NC 27704-2702 Ph: (919) 470-4000 |
News Archive
Health care providers are constantly evolving treatments for complicated conditions to provide patients with the greatest amount of benefit while avoiding any adverse effects, like scarring.
Cherwell Laboratories, specialists in products for process validation and environmental monitoring will present their comprehensive product range at the Aseptic Preparation and Dispensing of Medicines (APDM) Course, Leeds Trinity University on 9th & 10th July 2013.
The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis.
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 5 days ago
Dr. Stephen John Greene, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2301 Erwin Rd # Dumc3845, Durham, NC 27705 Phone: 919-684-8111 | |
Dr. Jacob Paul Feigal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Duke University Hospital Gme, Box 3951, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. David Keith Bright, MD, PHARM D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4205 Ben Franklin Blvd, Durham, NC 27704 Phone: 919-477-6900 Fax: 919-477-5081 | |
Yuri Anthony Fesko, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4101 N Roxboro St, Durham, NC 27704 Phone: 919-684-8111 | |
Mary E Klotman, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Jonathan Paul Piccini Sr., M.D., M.H.S. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. Deborah Anne Fisher, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 508 Fulton St, Durham, NC 27705 Phone: 919-286-6945 |